Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris

British Journal of Dermatology

Volumn 163, Issue 5, 2010, Pages 1085-1089

  Anderson, K S ^a   Petersson, S ^b   Wong, J ^a   Shubbar, E ^b   Lokko, N N ^a   Carlstrom M ^c   Enerback C ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Chemokines; Cytokines; Psoriasis

Indexed keywords

ALPHA2 INTERFERON; EOTAXIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; HUMAN; PHOTOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; ULTRAVIOLET B RADIATION; UPREGULATION;

BIOLOGICAL MARKERS; CYTOKINES; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; PSORIASIS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; ULTRAVIOLET THERAPY;

EID: 78249235034     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09990.x     Document Type: Article

References (19)

1. Pietrzak AT, Zalewska A, Chodorowska G, et al. Cytokines and anticytokines in psoriasis. Clin Chim Acta 2008; 394: 7 -21.
2. Jacob SE, Nassiri M, Kerdel FA, et al. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm 2003; 12: 309 -13.
3. Gomi T, Shiohara T, Munakata T, et al. Interleukin 1 alpha, tumor necrosis factor alpha, and interferon gamma in psoriasis. Arch Dermatol 1991; 127: 827 -30.
4. Anderson KS, Wong J, Polyak K, et al. Detection of psoriasin/S100A7 in the sera of patients with psoriasis. Br J Dermatol 2009; 160: 325 -32.
5. Saeed AI, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. BioTechniques 2003; 34: 374 -8.
6. Szodoray P, Alex P, Chappell-Woodward CM, et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford) 2007; 46: 417 -25.
7. Nickoloff BJ, Xin H, Nestle FO, et al. The cytokine and chemokine network in psoriasis. Clin Dermatol 2007; 25: 568 -73.
8. Illman J, Corringham R, Robinson D Jr, et al. Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol 2005; 3: 37 -50.
9. Pietrzak A, Miturski R, Krasowska D, et al. Concentration of an epidermal growth factor in blood serum of males during topical treatment of psoriasis. J Eur Acad Dermatol Venereol 1999; 12: 1 -5.
10. Nanney LB, Stoscheck CM, Magid M, et al. Altered [125I] epidermal growth factor binding and receptor distribution in psoriasis. J Invest Dermatol 1986; 86: 260 -5.
11. Cordero JB, Cozzolino M, Lu Y, et al. 1,25-Dihydroxyvitamin D down-regulates cell membrane growth-and nuclear growth-promoting signals by the epidermal growth factor receptor. J Biol Chem 2002; 277: 38965 -71.
12. Bonifati C, Ameglio F, Carducci M, et al. Interleukin-1-beta, interleukin-6, and interferon-gamma in suction blister fluids of involved and uninolved skin and in sera of psoriatic patients. Acta Derm Venereol (Stockh) 1994; 186 (Suppl.): 23 -4.
13. Dinarello CA,. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998; 16: 457 -99.
14. Bigler CF, Norris DA, Weston WL, et al. Interleukin-1 receptor antagonist production by human keratinocytes. J Invest Dermatol 1992; 98: 38 -44.
15. Juge-Aubry CE, Somm E, Giusti V, et al. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 2003; 52: 1104 -10.
16. Salmenniemi U, Ruotsalainen E, Pihlajamaki J, et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 2004; 110: 3842 -8.
17. Naldi L, Addis A, Chimenti S, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology 2008; 217: 365 -73.
18. Amital H, Barak V, Winkler RE, Rubinow A,. Impact of treatment with infliximab on serum cytokine profile of patients with rheumatoid and psoriatic arthritis. Ann NY Acad Sci 2007; 1110: 649 -60.
19. Oliver JC, Bland LA, Oettinger CW, et al. Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. Lymphokine Cytokine Res 1993; 12: 115 -20.